The kallikrein-kinin pathway is dysregulated in HAE1
Uncontrolled plasma kallikrein leads to excessive bradykinin production2
Figure adapted from Valerieva et al, Bender et al, and Csuka et al.3-5
C1-INH=C1 esterase inhibitor; cHMWK=cleaved high molecular weight kininogen; FXII=factor XII; FXIIa=factor XIIa; HMWK=high molecular weight kininogen; PKa=activated plasma kallikrein.
An established mAb targeting the inhibition of plasma kallikrein to reduce the release of bradykinin1
TAKHZYRO provides targeted inhibition of plasma kallikrein, a critical regulator of bradykinin, known to cause HAE attacks1
Figure adapted from Valerieva et al, Bender et al, and Csuka et al.3-5
C1-INH=C1 esterase inhibitor; HMWK= high molecular weight kininogen; FXII=factor XII; FXIIa=factor XIIa; PKa=activated plasma kallikrein.
See the data across 4 studies
Explore the results of the HELP study, the HELP open-label extension study, Real World EMPOWER study, and the SPRING study.
References: 1. Takhzyro. Prescribing information. Dyax Corp; 2025. 2. Banerji A, Busse P, Shennak M, et al. N Engl J Med. 2017;376(8):717-728. doi:10.1056/NEJMoa1605767 3. Valerieva A, Longhurst HJ. Front Allergy. 2022;3:952233. doi: 10.3389/falgy.2022.952233 4. Bender L, Weidmann H, Rose-John S, et al. Front Immunol. 2017;8:1115. doi:10.3359/fimmu.2017.01115 5. Csuka D, Veszeli N, Imreh É, et al. Orphanet J Rare Dis. 2015;10:132. doi:10.1186/s13023-015-0351-5